as of 01-15-2026 3:57pm EST
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
| Founded: | 1994 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 3.5M | IPO Year: | N/A |
| Target Price: | $9750.00 | AVG Volume (30 days): | 555.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.36 - $46.60 | Next Earning Date: | 02-03-2026 |
| Revenue: | $560,000 | Revenue Growth: | -16.04% |
| Revenue Growth (this year): | 461.72% | Revenue Growth (next year): | -20.66% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
See how CANF stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.